NCT06694090Not yet recruiting
Von Willebrand Factor Levels in Patients With Liver Cirrhosis and Portal Hypertension
Source: ClinicalTrials.gov · Last updated 19 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Verify Von willebrand factor role in patients with liver cirrhosis and portal hypertension
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 67 (estimated)
- First submitted
- 14 Nov 2024
- Start date
- 15 Nov 2024
- Primary completion date
- 15 Nov 2025
- Lead sponsor
- Assiut University
- Diseases
- High blood pressure
- NCT number
- NCT06694090
What you commit to
- Study type: Observational
- Planned participants: 67
- From 15 Nov 2024 to the primary completion date, 15 Nov 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previous liver transplantation.
- any medication affect VWF level.
Other illness
- acute liver disease
- any hereditary or acquired diseases that affect VWF level.
- sepsis and infections (including spontaneous bacterial peritonitis), patients with any infectious symptoms at the time of study (increasing VWF Ag levels).
- active extrahepatic malignancies.
Who the study is looking for
- adult patient \>18 years
- both sex male and female
- all stages of liver cirrhosis (compensated and decompensated)
Age in the registry: 18 years to 65 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.